Liver Cancer

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, usually arising in the setting of chronic liver disease. Major risk factors include hepatitis B or C infection, cirrhosis from any cause (alcohol, fatty liver disease), aflatoxin exposure, and certain metabolic conditions. HCC is often diagnosed late because the diseased liver may not show symptoms until cancer is advanced. Treatment depends on stage and liver function and may include surgery, transplant, ablation, chemoembolization, or systemic therapy.

CRITICAL: Liver cancer requires comprehensive oncological management. Treatment decisions depend on tumor stage, liver function (Child-Pugh score), and performance status. Options include surgical resection, liver transplantation (for appropriate candidates), ablation, transarterial chemoembolization (TACE), radioembolization, or systemic therapies (sorafenib, lenvatinib, immunotherapy). These supplements may provide supportive benefit but DO NOT treat cancer. Always discuss supplements with your oncology team as some may interact with treatments. Addressing underlying liver disease (viral hepatitis, alcohol) is crucial.

* Vitamin D deficiency is very common in liver disease (the liver converts vitamin D to its active form). Low vitamin D levels are associated with worse HCC outcomes. Supplementation supports immune function and may be beneficial.

* Omega-3 Fatty Acids have anti-inflammatory effects and may help with cancer-related weight loss (cachexia). They also support liver function.

* Vitamin K has shown potential antiproliferative effects against HCC in some studies, particularly vitamin K2 (menatetrenone). Deficiency is common in liver disease due to impaired absorption and storage.

* Milk Thistle (Silymarin) has hepatoprotective and antioxidant properties. It may help protect remaining liver function and reduce treatment side effects.

* Curcumin has shown anti-cancer effects against HCC in laboratory studies, including inhibiting cell proliferation and inducing apoptosis.

* Branched-Chain Amino Acids (BCAAs) are often depleted in cirrhosis. Supplementation can help maintain muscle mass, improve nutritional status, and may improve outcomes after HCC treatment.

* Zinc deficiency is very common in chronic liver disease and contributes to complications. Supplementation supports liver function and immune health.

* Selenium deficiency has been associated with increased liver cancer risk, particularly in areas with endemic low selenium levels.

Expected timeline: Nutritional support is ongoing throughout treatment. Discuss any supplements with your oncologist before starting.